- Home
- Clinical Care
- Bone density and fracture risk: when to ask about a DXA scan
Bone density and fracture risk: when to ask about a DXA scan
Bone health
Osteoporosis can progress quietly until a fracture occurs. A bone density test can help clinicians assess risk before that happens, alongside a person’s age, medical history and other factors. Knowing when to ask about a scan can open a useful conversation about prevention and treatment.
In its November 2026 guide, NIH News in Health explains that osteoporosis weakens bone and raises the chance of a break. It affects both women and men. Age, family history, certain health conditions and long-term use of some medicines can contribute to risk. Many people do not know they have osteoporosis until a bone breaks.
Bone is living tissue
Bone is continually renewed. When bone is lost faster than it is replaced, or when too little new bone is formed, its strength can decline. NIH notes that people generally lose bone density as they age. After menopause, lower estrogen levels can accelerate bone loss. Men can also develop osteoporosis, sometimes in association with illnesses or long-term use of medicines that affect bone.
Not all fractures mean a person has osteoporosis. But a break following a minor fall or other low-trauma event is a reason to discuss bone health with a clinician. The hip, spine and wrist are common fracture sites. A prior fracture and a history of falls are among the details that can help guide an assessment.
What a DXA scan can show
Dual-energy X-ray absorptiometry, or DXA, measures bone mineral density. A result below the normal range but above the osteoporosis threshold may be called osteopenia. It can signal increased fracture risk, but not everyone with osteopenia will develop osteoporosis. A clinician interprets the result with clinical risk factors rather than treating a number as the whole story.
A scan measures density; it cannot by itself describe every aspect of bone quality or predict with certainty who will break a bone. A fracture-risk assessment may combine the test result with information such as age and prior fractures. The clinician can explain how the result affects decisions about follow-up and whether treatment is appropriate.
Who should discuss screening?
NIH notes that routine screening is recommended for women aged 65 and older, while some people may need assessment earlier because of risk factors. These may include a previous fracture, falls, certain underlying conditions or long-term corticosteroid use. Recommendations and eligibility vary by country and individual circumstances.
Bring a list of medicines and relevant medical history to the conversation. Ask what the test is expected to add, how the result will be interpreted, and whether there are other causes of bone loss to consider. A clinician can also discuss whether a scan is useful for men or younger people based on their individual risk.
Protecting bones over time
Weight-bearing activity and resistance training, adapted to a person’s abilities, can support bone health. Walking, dancing and strength exercises are examples NIH discusses. People with a fracture, osteoporosis or another medical condition should ask their care team which activities and movements are safe for them.
Adequate calcium, vitamin D and protein also matter. Food can contribute to those needs, and a healthcare professional can help determine whether a supplement is appropriate. Avoiding smoking, limiting alcohol and reducing fall hazards are useful parts of a broader plan. Good lighting, clear walking paths and attention to balance or vision can be part of a fall-prevention discussion.
Medicines are another option for some people at higher fracture risk. NIH describes treatments that slow bone breakdown and research into treatments that build bone. Their benefits, risks and suitability depend on the patient. A DXA result is one piece of a shared decision, not a treatment plan to interpret alone.
Source: NIH News in Health, Protect Your Bone Health, November 2026.
Image: physiotherapist supporting a back exercise. Illustrative photograph by Funkcinės Terapijos Centras / Pexels; it does not show a DXA scan.
Clinical Care
View moreWhen someone has an infection, choosing the right treatment can depend on more than identifying symptoms. A laboratory test can help clinicians find the cause and, in some circumstances, determine which medicines are likely to work. On 16 November, the World Health Organization published an essential package of diagnostic tests for bacterial and fungal infections and antimicrobial resistance. It sets out a prioritized range of tests for different levels of care, from primary care to referral hospitals. The package includes rapid tests, microscopy, culture, serology and molecular methods. Some tests help identify an organism; antimicrobial susceptibility testing can help show whether a bacterium or fungus is likely to respond to particular medicines. Which test is appropriate depends on the patient, the suspected infection and the resources available. Testing also has limits. Results must be interpreted alongside the clinical picture, and not every infection requires the same test. For a seriously ill patient, a clinician may need to start treatment before results are available and adjust it later when more information arrives. WHO says access to reliable diagnostics remains uneven, particularly in low- and middle-income countries. Its package is intended to help health systems plan services and improve access to timely, quality-assured testing. During World AMR Awareness Week, the message is straightforward: better diagnosis can support better treatment decisions, while helping health systems track drug resistance. Patients should follow their clinician’s advice and ask what a test result means for their care. Source: World Health Organization, 16 November 2026.
Taking blood pressure at home: small steps that make readings more useful
Bone density and fracture risk: when to ask about a DXA scan
Diabetes and kidney health: the checks that can find trouble early
Some mornings, tiredness has an obvious explanation: a late night, a stressful week, or a child who kept waking up. But when exhaustion continues even after you have tried to rest, it can be difficult to know whether to wait it out or ask for help. Fatigue is a symptom, not a diagnosis. The most useful question is often: what else has changed, and how long has this been going on? Why you might feel tired Not getting enough sleep is one possible explanation, but it is far from the only one. Stress, low mood, pregnancy, menopause, recent illness and some medicines can all contribute. Persistent fatigue can also occur with conditions such as iron deficiency anaemia, diabetes, thyroid disorders or sleep apnoea. Other symptoms can provide clues. Someone with sleep apnoea might snore loudly or wake up gasping. A person with anaemia may also notice breathlessness or palpitations. These combinations can help a clinician decide what to investigate, but they cannot confirm a diagnosis on their own. When should you see a clinician? Make an appointment if you have been tired for a few weeks without a clear reason, if fatigue is affecting daily life, or if it comes with changes such as unexplained weight loss, mood changes or interrupted breathing during sleep. Before the appointment, note when the fatigue started, how you sleep, any other symptoms and any medicines or supplements you take. Depending on your history and examination, a clinician may suggest blood tests or further assessment. Seek emergency care for severe symptoms such as chest pain, severe difficulty breathing, fainting or new confusion. The takeaway Rest and a consistent sleep routine can help some people, but persistent fatigue deserves attention. You do not need to find the answer on your own before asking for help. Source: NHS: Tiredness and fatigue. Illustrative photograph: Ron Lach / Pexels.
Hair shedding or hair loss? What your hairbrush can and can’t tell you
For a small group with rectal cancer, immunotherapy changes the treatment conversation
After the smoke clears, wildfire survivors may still need lung-health follow-up
GRAYMEDY RESEARCH ANALYSIS · November 8, 2026 Before someone can weigh the benefits and burdens of research participation, they need a meaningful opportunity to consider it. A newly published national survey of U.S. women places that opportunity under scrutiny. An invitation gap Doruntina Fida, Therese A. Rajasekera, Primavera A. Spagnolo and colleagues surveyed 5,301 U.S. women aged 18–70. The peer-reviewed accepted paper appeared in Scientific Reports on November 7, 2026. The authors reported that 23% expressed definite willingness to participate and 60% answered maybe, while 11% said they had been invited and 7% had enrolled. Among respondents reporting race, the sample was predominantly White. Adjusted analyses associated lower willingness with being Black rather than White, while higher education and multimorbidity were associated with greater willingness. Respondents’ preferred information, motivations and perceived barriers also differed. These are associations within the surveyed population, rather than explanations of individual choices. Interest is not consent An expression of interest in a survey does not tell researchers whether someone would join a particular trial. A real decision depends on the intervention, uncertainty, visits, travel, childcare, costs and other personal circumstances. The maybe response is especially important: it represents a question requiring discussion rather than a commitment waiting to be activated. Graymedy’s reading is that the invitation gap deserves attention without turning willingness into a recruitment target that overrides autonomy. Improving access means giving eligible people understandable choices and enough room to decline. It does not mean assuming that everyone who is interested in research should enrol. What the design cannot resolve This was a cross-sectional online survey, not an experiment testing an invitation programme. Self-reported experience is subject to recall, and the people answering an online survey may differ from women who did not participate. The results therefore cannot establish a national causal explanation for underrepresentation. Race should not be read as a biological explanation for willingness. The study considers social and structural conditions alongside healthcare access, socioeconomic circumstances and health. A group-level result also cannot tell a clinician what an individual woman wants or why she might decline. Asking and listening remain essential. Turning a finding into a care question The authors call for evaluation of culturally responsive engagement, trust-building and approaches that reduce burden. Those are strategies to test, rather than interventions proven effective by this survey. A useful next study would measure whether changes improve informed opportunities and representation while preserving the quality of consent. At a service level, one possible audit would track eligible patients, invitations offered, invitations understood and participation decisions. Recording reasons for not being invited could reveal a different problem from recording reasons for declining. Such an audit would also need to protect privacy and avoid making research participation feel like a condition of good care. The central message is modest but consequential: low enrolment cannot automatically be equated with low interest. Research teams need to understand the route between a person’s willingness to hear more and the practical opportunity to make an informed choice. Sources and publication dates Fida et al., Scientific Reports, November 7, 2026; accepted article version Independent editorial analysis of published research; no interview or endorsement is implied. Image credit: National Cancer Institute, image 4187, circa 2006. Public domain. Original image source.
Diet during antibiotics: a transplant study puts the hospital menu under scrutiny
A clinic on wheels brings a survival signal—and a harder question about addiction care